AAPL344.52-3.21 (-0.92%) ▼|ABBV286.57+0.93 (+0.33%) ▲|ABT104.60+0.90 (+0.87%) ▲|ACN246.30-3.08 (-1.23%) ▼|ADBE255.70-8.12 (-3.08%) ▼|AMAT391.12+13.88 (+3.68%) ▲|AMD528.90+12.11 (+2.34%) ▲|AMGN440.95+1.69 (+0.38%) ▲|AMT190.48+1.51 (+0.80%) ▲|AMZN248.45+0.45 (+0.18%) ▲|AVGO329.90+8.22 (+2.55%) ▲|AXP314.28+1.06 (+0.34%) ▲|BA188.22-0.13 (-0.07%) ▼|BAC50.94+0.38 (+0.74%) ▲|BKNG152.02-3.82 (-2.45%) ▼|BLK1,130.41+12.16 (+1.09%) ▲|BMY61.25-0.23 (-0.37%) ▼|BNY147.79+3.15 (+2.18%) ▲|BRK-B545.29+3.10 (+0.57%) ▲|C121.74+1.12 (+0.93%) ▲|CAT692.55+7.18 (+1.05%) ▲|CL93.02-1.02 (-1.08%) ▼|CMCSA22.11-0.59 (-2.58%) ▼|COF202.84+1.50 (+0.75%) ▲|COP151.23+0.43 (+0.29%) ▲|COST1,003.60+0.28 (+0.03%) ▲|CRM243.79-4.79 (-1.93%) ▼|CSCO109.71+3.21 (+3.01%) ▲|CVS92.60-0.88 (-0.94%) ▼|CVX232.26-0.95 (-0.41%) ▼|DE637.82-8.33 (-1.29%) ▼|DHR232.14+1.64 (+0.71%) ▲|DIS110.20-2.33 (-2.07%) ▼|DUK124.54-0.45 (-0.36%) ▼|EMR161.98+0.39 (+0.24%) ▲|FDX300.33+1.61 (+0.54%) ▲|GD353.80+4.44 (+1.27%) ▲|GE288.50+2.86 (+1.00%) ▲|GEV854.16+39.16 (+4.80%) ▲|GILD158.99+2.95 (+1.89%) ▲|GM76.55+0.63 (+0.83%) ▲|GOOG316.34-0.94 (-0.30%) ▼|GOOGL319.72-0.49 (-0.15%) ▼|GS896.81+21.13 (+2.41%) ▲|HD318.47-1.37 (-0.43%) ▼|HON219.80-1.35 (-0.61%) ▼|IBM253.51-0.05 (-0.02%) ▼|INTC90.87+3.91 (+4.49%) ▲|INTU335.37-8.02 (-2.34%) ▼|ISRG453.13+0.84 (+0.19%) ▲|JNJ266.14+2.33 (+0.88%) ▲|JPM334.54+2.96 (+0.89%) ▲|KO92.45-0.26 (-0.28%) ▼|LIN510.62+1.79 (+0.35%) ▲|LLY1,281.47+8.01 (+0.63%) ▲|LMT624.04+19.86 (+3.29%) ▲|LOW198.06-0.63 (-0.31%) ▼|LRCX239.36+9.26 (+4.02%) ▲|MA613.69-9.91 (-1.59%) ▼|MCD250.37+1.91 (+0.77%) ▲|MDLZ63.00-0.81 (-1.26%) ▼|MDT94.60-0.82 (-0.85%) ▼|META642.55-0.07 (-0.01%) ▼|MMM172.70-0.77 (-0.44%) ▼|MO73.67-0.65 (-0.87%) ▼|MRK141.97-3.30 (-2.27%) ▼|MS184.21+4.72 (+2.63%) ▲|MSFT529.79+5.28 (+1.01%) ▲|MU906.74+29.19 (+3.33%) ▲|NEE82.23+0.13 (+0.16%) ▲|NFLX63.42-2.44 (-3.70%) ▼|NKE37.81+0.51 (+1.35%) ▲|NOW155.78-3.19 (-2.00%) ▼|NVDA215.56+4.60 (+2.18%) ▲|ORCL126.45+0.29 (+0.23%) ▲|PEP135.76-0.01 (-0.01%) ▼|PFE29.90-0.14 (-0.45%) ▼|PG159.85-1.17 (-0.73%) ▼|PLTR198.60+1.85 (+0.94%) ▲|PM202.40+2.93 (+1.47%) ▲|QCOM178.73+2.82 (+1.60%) ▲|RTX196.03+5.02 (+2.63%) ▲|SBUX102.14+1.34 (+1.33%) ▲|SCHW90.00-0.58 (-0.64%) ▼|SO92.69-0.20 (-0.22%) ▼|SPG212.86+1.23 (+0.58%) ▲|T20.92-0.02 (-0.07%) ▼|TMO679.06+5.24 (+0.78%) ▲|TMUS145.53-1.02 (-0.69%) ▼|TSLA394.39+22.17 (+5.96%) ▲|TXN291.80+7.11 (+2.50%) ▲|UBER66.33-0.37 (-0.55%) ▼|UNH411.11-6.98 (-1.67%) ▼|UNP294.93+2.06 (+0.70%) ▲|UPS100.08-0.98 (-0.97%) ▼|USB59.85+0.27 (+0.45%) ▲|V403.66-4.26 (-1.04%) ▼|VZ43.17-1.50 (-3.35%) ▼|WFC83.11+0.72 (+0.87%) ▲|WMT120.57+0.68 (+0.57%) ▲|XOM183.77+0.56 (+0.30%) ▲|AAPL344.52-3.21 (-0.92%) ▼|ABBV286.57+0.93 (+0.33%) ▲|ABT104.60+0.90 (+0.87%) ▲|ACN246.30-3.08 (-1.23%) ▼|ADBE255.70-8.12 (-3.08%) ▼|AMAT391.12+13.88 (+3.68%) ▲|AMD528.90+12.11 (+2.34%) ▲|AMGN440.95+1.69 (+0.38%) ▲|AMT190.48+1.51 (+0.80%) ▲|AMZN248.45+0.45 (+0.18%) ▲|AVGO329.90+8.22 (+2.55%) ▲|AXP314.28+1.06 (+0.34%) ▲|BA188.22-0.13 (-0.07%) ▼|BAC50.94+0.38 (+0.74%) ▲|BKNG152.02-3.82 (-2.45%) ▼|BLK1,130.41+12.16 (+1.09%) ▲|BMY61.25-0.23 (-0.37%) ▼|BNY147.79+3.15 (+2.18%) ▲|BRK-B545.29+3.10 (+0.57%) ▲|C121.74+1.12 (+0.93%) ▲|CAT692.55+7.18 (+1.05%) ▲|CL93.02-1.02 (-1.08%) ▼|CMCSA22.11-0.59 (-2.58%) ▼|COF202.84+1.50 (+0.75%) ▲|COP151.23+0.43 (+0.29%) ▲|COST1,003.60+0.28 (+0.03%) ▲|CRM243.79-4.79 (-1.93%) ▼|CSCO109.71+3.21 (+3.01%) ▲|CVS92.60-0.88 (-0.94%) ▼|CVX232.26-0.95 (-0.41%) ▼|DE637.82-8.33 (-1.29%) ▼|DHR232.14+1.64 (+0.71%) ▲|DIS110.20-2.33 (-2.07%) ▼|DUK124.54-0.45 (-0.36%) ▼|EMR161.98+0.39 (+0.24%) ▲|FDX300.33+1.61 (+0.54%) ▲|GD353.80+4.44 (+1.27%) ▲|GE288.50+2.86 (+1.00%) ▲|GEV854.16+39.16 (+4.80%) ▲|GILD158.99+2.95 (+1.89%) ▲|GM76.55+0.63 (+0.83%) ▲|GOOG316.34-0.94 (-0.30%) ▼|GOOGL319.72-0.49 (-0.15%) ▼|GS896.81+21.13 (+2.41%) ▲|HD318.47-1.37 (-0.43%) ▼|HON219.80-1.35 (-0.61%) ▼|IBM253.51-0.05 (-0.02%) ▼|INTC90.87+3.91 (+4.49%) ▲|INTU335.37-8.02 (-2.34%) ▼|ISRG453.13+0.84 (+0.19%) ▲|JNJ266.14+2.33 (+0.88%) ▲|JPM334.54+2.96 (+0.89%) ▲|KO92.45-0.26 (-0.28%) ▼|LIN510.62+1.79 (+0.35%) ▲|LLY1,281.47+8.01 (+0.63%) ▲|LMT624.04+19.86 (+3.29%) ▲|LOW198.06-0.63 (-0.31%) ▼|LRCX239.36+9.26 (+4.02%) ▲|MA613.69-9.91 (-1.59%) ▼|MCD250.37+1.91 (+0.77%) ▲|MDLZ63.00-0.81 (-1.26%) ▼|MDT94.60-0.82 (-0.85%) ▼|META642.55-0.07 (-0.01%) ▼|MMM172.70-0.77 (-0.44%) ▼|MO73.67-0.65 (-0.87%) ▼|MRK141.97-3.30 (-2.27%) ▼|MS184.21+4.72 (+2.63%) ▲|MSFT529.79+5.28 (+1.01%) ▲|MU906.74+29.19 (+3.33%) ▲|NEE82.23+0.13 (+0.16%) ▲|NFLX63.42-2.44 (-3.70%) ▼|NKE37.81+0.51 (+1.35%) ▲|NOW155.78-3.19 (-2.00%) ▼|NVDA215.56+4.60 (+2.18%) ▲|ORCL126.45+0.29 (+0.23%) ▲|PEP135.76-0.01 (-0.01%) ▼|PFE29.90-0.14 (-0.45%) ▼|PG159.85-1.17 (-0.73%) ▼|PLTR198.60+1.85 (+0.94%) ▲|PM202.40+2.93 (+1.47%) ▲|QCOM178.73+2.82 (+1.60%) ▲|RTX196.03+5.02 (+2.63%) ▲|SBUX102.14+1.34 (+1.33%) ▲|SCHW90.00-0.58 (-0.64%) ▼|SO92.69-0.20 (-0.22%) ▼|SPG212.86+1.23 (+0.58%) ▲|T20.92-0.02 (-0.07%) ▼|TMO679.06+5.24 (+0.78%) ▲|TMUS145.53-1.02 (-0.69%) ▼|TSLA394.39+22.17 (+5.96%) ▲|TXN291.80+7.11 (+2.50%) ▲|UBER66.33-0.37 (-0.55%) ▼|UNH411.11-6.98 (-1.67%) ▼|UNP294.93+2.06 (+0.70%) ▲|UPS100.08-0.98 (-0.97%) ▼|USB59.85+0.27 (+0.45%) ▲|V403.66-4.26 (-1.04%) ▼|VZ43.17-1.50 (-3.35%) ▼|WFC83.11+0.72 (+0.87%) ▲|WMT120.57+0.68 (+0.57%) ▲|XOM183.77+0.56 (+0.30%) ▲|
16.7 C
New York
Monday, October 26, 2026

Tag: nanoparticle

Osivax Announces Last Patient Last Visit in Phase 2a Trial Evaluating a Booster Dose of Broad-Spectrum Influenza Vaccine OVX836 s release

Lyon, France – June 5, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses, today announced that all participants have completed their final visit in the Phase 2a clinical booster trial (NCT06582277) evaluating OVX836, Osivax’ broad-spectrum influenza A vaccine candidate. Osivax expects to announce final results from the booster trial in H2 2025.

CancerVax Achieves Major Milestone with Successful Creation of Cell Targeting Nanoparticle

Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells
Recent independent analyses confirmed that the Company has successfully created a ligand conjugated nanoparticle that can target specific biomarkers on the surface of cancer cells

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNanoparticle